Mirati Therapeutics' GAAP loss for six months of 2021 was $302.11 million, up 78% from $166.514 million in the prior year. 2021 was $302.11 million, up 78.2% from $169.514 million in the previous year. The company did not generate revenue. A year earlier the figure was $267,000.